WAINUA® (eplontersen) 45 mg injection for subcutaneous use

AstraZeneca Access 360™

A COMPENDIUM OF GENERALIZED hATTR-PN REFERENCES FOR WAINUA® (eplontersen)

When completing a prior authorization, precertification, reauthorization, or appeal request for WAINUA for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN), insurers may require documentation, including clinical notes and impressions, lab results, and other relevant information. The selection of references below, including the WAINUA Prescribing Information and published literature, may be helpful when completing the request to your patient's insurance company.

This compendium is not inclusive of all US and global data and literature for hATTR-PN or WAINUA. This should be used for informational purposes only and does not constitute legal advice or official guidance from payers. **It is not intended to influence reimbursement decisions or replace the independent medical judgment of a healthcare provider.** AstraZeneca does not guarantee that the use or citation of any literature listed below will result in coverage or reimbursement for WAINUA.

Abstracts for the references cited below are available online. Most of the publications permit access to and download of the articles for personal use; some publications require that the article be purchased in order to gain access.

For ease of use, each reference is categorized by topic:

WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Assessment tools

- **Polyneuropathy Disability (PND) score and Familial Amyloid Polyneuropathy (FAP) stage:** Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol*. 2021;268(6):2109-2122.
- **Neuropathy Impairment Score (NIS):** Dyck PJB, González-Duarte A, Obici L, et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: from NIS to mNIS + 7. *J Neurol Sci*. 2019;405:116424.
- Conceição I, Coelho T, Rapezzi C, et al. Assessment of patients with hereditary transthyretin amyloidosis - understanding the impact of management and disease progression. *Amyloid*. 2019;26(3):103-111.
- Coelho T, Vinik A, Vinik EJ, Tripp T, Packman J, Grogan DR. Clinical measures in transthyretin familial amyloid polyneuropathy. *Muscle Nerve.* 2017;55(3):323-332.

Burden of disease

- Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. *Am J Manag Care.* 2017;23(7 Suppl):S107-S112.
- Stewart M, Shaffer S, Murphy B, et al. Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers. *Neurol Ther.* 2018;7(2):349-364.
- Lovley A, Raymond K, Guthrie SD, Pollock M, Sanchorawala V, White MK. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. *J Patient Rep Outcomes.* 2021;5(1):3.
- Inês M, Coelho T, Conceição I, Ferreira L, de Carvalho M, Costa J. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. *Orphanet J Rare Dis.* 2020;15(1):67.
- Schmidt HH, Waddington-Cruz M, Botteman MF, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. *Muscle Nerve.* 2018;57(5):829-837.

Please see Important Safety Information on page 3 and the US full Prescribing Information for WAINUA.

Clinical presentation and disease progression

- Conceição I, González-Duarte A, Obici L, et al. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. *J Peripher Nerv Syst.* 2016;21(1):5-9.
- Gonzalez-Duarte A, Valdés-Ferrer SI, Cantú-Brito C. Characteristics and natural history of autonomic involvement in hereditary ATTR amyloidosis: a systematic review. *Clin Auton Res.* 2019;29(suppl 1):1-9.
- Nativi-Nicolau JN, Karam C, Khella S, Maurer MS. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. *Heart Fail Rev.* 2022;27(3):785-793.
- Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol.* 2021;268(6):2109-2122.
- Lin X, Yarlas A, Vera-Llonch M, et al. Rate of neuropathic progression in hereditary transthyretin amyloidosis with polyneuropathy and other peripheral neuropathies: a systematic review and meta-analysis. *BMC Neurol.* 2021;21(1):70.
- Halabi A, Sanjurjo V, Papas M, et al. Polyneuropathy symptoms precede diagnosis of cardiomyopathy among individuals with transthyretin amyloidosis. Presented at: American Academy of Neurology Annual Meeting; April 18-22, 2026; Chicago, IL.

WAINUA® (eplontersen) Prescribing Information and publications in hATTR-PN

- WAINUA® (eplontersen) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
- Coelho T, Marques W Jr, Dasgupta NR, et al. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy [article and supplementary online content]. *JAMA.* 2023;330(15):1448-1458.
- Coelho T, Ando Y, Benson MD, et al. Design and rationale of the global phase 3 NEURO-TTRansform study of antisense oligonucleotide AKCEA-TTR-L_{Rx} (ION-682884-CS3) in hereditary transthyretin-mediated amyloid polyneuropathy. *Neurol Ther.* 2021;10(1):375-389.
- Berk J, Coelho T, Conceição I, et al. Long-term efficacy and safety of eplontersen in patients with hereditary transthyretin amyloidosis with polyneuropathy: initial report from the open-label extension of the NEURO-TTRansform study. Presented at: 5th International ATTR Amyloidosis Meeting 2025; September 25-26, 2025; Baveno, Italy.
- Wixner J, Berk JL, Adams D, et al. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. *Amyloid.* 2025;32(1):29-38.

Guidelines and expert consensus

- Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. *J Neurol.* 2021;268(6):2109-2122.
- Karam C, Mauermann ML, Gonzalez-Duarte A, et al. Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: recommendations from a panel of experts. *Muscle Nerve.* 2024;69(3):273-287.
- Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. *BMC Fam Pract*. 2020;21(1):198.

Please see Important Safety Information on page 3 and the US full Prescribing Information for WAINUA.

KEY RESOURCES AVAILABLE TO YOU

- The **WAINUA Sample Appeal Letter Guide:** provides guidance on how to prepare an appeal
- The **WAINUA Sample Letter of Medical Necessity Guide:** provides guidance on how to prepare a letter of medical necessity when responding to a request from a patient's health benefits company
- The **Access and Reimbursement Guide** is a resource that provides education and support about the access and reimbursement process
- The **WAINUA Full Prescribing Information** provides details and directions on how to prescribe WAINUA and pertinent efficacy and safety data
- The **Free Limited Supply (FLS) Request** provides a free, short-term supply of WAINUA for eligible patients who are denied immediate access or are awaiting insurance coverage determination. Please note that FLS is a temporary program and does not replace existing affordability programs that may be more appropriate for long-term access barriers

INDICATION

WAINUA injection, for subcutaneous use, 45 mg is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Reduced Serum Vitamin A Levels and Recommended Supplementation** WAINUA leads to a decrease in serum vitamin A levels. Supplement with recommended daily allowance of vitamin A. Refer patient to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur.

ADVERSE REACTIONS

Most common adverse reactions (≥9% in WAINUA-treated patients) were vitamin A decreased (15%) and vomiting (9%).

Please see the US full Prescribing Information for WAINUA, available at www.WAINUApi.com.

You are encouraged to report negative side effects of AstraZeneca prescription drugs by calling 1-800-236-9933. If you prefer to report these to the FDA, call 1-800-FDA-1088.

For additional access resources, please see AstraZeneca Access 360™'s Forms and Resources or scan the QR code to find the right access and support options for you and your WAINUA patients.

WAINUA® (eplontersen) 45 mg injection for subcutaneous use

AstraZeneca Access 360™

AstraZeneca IONIS